Literature DB >> 16872437

Characteristics of loss of heterozygosity in large cell neuroendocrine carcinomas of the lung and small cell lung carcinomas.

Tomoyo Takeuchi1, Yuko Minami, Tatsuo Iijima, Toru Kameya, Hisao Asamura, Masayuki Noguchi.   

Abstract

Large cell neuroendocrine carcinoma (LCNEC) of the lung is a new entity. Besides morphological characteristics, its molecular biological features have been investigated by many researchers and compared to those of other neuroendocrine carcinomas, small cell lung carcinoma (SCLC) and carcinoid tumor (CT). However, there are few reports that show the significantly different genetic characteristics between them. The purpose of the present paper was to study the frequency of loss of heterozygosity (LOH) at chromosome 3p (3p14.2) in 38 neuroendocrine carcinomas of the lung (13 LCNEC, 11 SCLC and 14 CT) and 10 large cell carcinomas (LCC). The frequencies of LOH at 3p14.2 were 69.2% in LCNEC, 81.8% in SCLC, 50.0% in LCC and 7.14% in CT. Those at 22q13.3 were 30.8% in LCNEC, 72.7% in SCLC, 45.5% in LCC and 7.14% in CT. In particular, the frequency of SCLC with LOH at both 3p14.2 and 22q13.3 (63.6%) was significantly higher than that of LCNEC (15.4%). LCNEC and SCLC had different characteristics of LOH patterns at 3p14.2 and 22q13.3. The combined analysis of the LOH at 3p14.2 and 22q13.3 is thought to be useful for differential diagnosis between LCNEC and SCLC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16872437     DOI: 10.1111/j.1440-1827.2006.01985.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  5 in total

1.  The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.

Authors:  Minglei Zhuo; Yanfang Guan; Xue Yang; Lingzhi Hong; Yuqi Wang; Zhongwu Li; Runzhe Chen; Hussein A Abbas; Lianpeng Chang; Yuhua Gong; Nan Wu; Jia Zhong; Wenting Chen; Hanxiao Chen; Zhi Dong; Xiang Zhu; Jianjie Li; Yuyan Wang; Tongtong An; Meina Wu; Ziping Wang; Jiayin Wang; Emily B Roarty; Waree Rinsurongkawong; Jeff Lewis; Jack A Roth; Stephen G Swisher; J Jack Lee; John V Heymach; Ignacio I Wistuba; Neda Kalhor; Ling Yang; Xin Yi; P Andrew Futreal; Bonnie S Glisson; Xuefeng Xia; Jianjun Zhang; Jun Zhao
Journal:  Clin Cancer Res       Date:  2019-11-06       Impact factor: 12.531

Review 2.  Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data.

Authors:  Luisella Righi; Marco Volante; Ida Rapa; Giorgio V Scagliotti; Mauro Papotti
Journal:  Virchows Arch       Date:  2007-08-08       Impact factor: 4.064

3.  Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA.

Authors:  Xianguang Bai; Ming Yi; Xichao Xia; Shengnan Yu; Xinhua Zheng; Kongming Wu
Journal:  Cancer Manag Res       Date:  2018-09-28       Impact factor: 3.989

4.  Loss of the integrin-activating transmembrane protein Fam38A (Piezo1) promotes a switch to a reduced integrin-dependent mode of cell migration.

Authors:  Brian J McHugh; Amanda Murdoch; Christopher Haslett; Tariq Sethi
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

5.  Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CgA, Syn and Napsin A.

Authors:  Yunlong Dong; Yongwen Li; Renwang Liu; Ying Li; Hongbing Zhang; Hongyu Liu; Jun Chen
Journal:  Oncol Lett       Date:  2020-01-23       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.